Terms: = Endocrine gland cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C AND Treatment
3 results:
1. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation.
Kawasaki Y; Hijioka S; Nagashio Y; Maruki Y; Ohba A; Takeshita K; Takasaki T; Agarie D; Hagiwara Y; Hara H; Okamoto K; Yamashige D; Kondo S; Morizane C; Ueno H; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Tamada K; Hiraoka N; Saito Y; Okusaka T
J Gastroenterol; 2023 Jul; 58(7):693-703. PubMed ID: 37154933
[TBL] [Abstract] [Full Text] [Related]
3. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract] [Full Text] [Related]